Management Goals of management of an open corneal injury are to ensure a watertight globe to prevent hypotony and infection, reestablish original anatomy as much as possible, and lastly, restore ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” and 1 day of acute “9 out of 10” left eye pain.She had a medical history of ...

Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for the treatment of neurotrophic keratitis (NK), a degenerative corneal disease ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design ...

Health officials have urgently recalled over 11,000 eye drops due to fears over contamination that could potentially cause serious eye infections and even blindness.

Find the latest Cornea and External Disease and Ophthalmology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

Xerophthalmia is an eye disease caused by vitamin A deficiency. Learn more about what causes it, what to expect, and more.